1. An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management
   Yiyu Cheng et al, 2023, Frontiers in Immunology CrossRef
2. Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study
   C. Ertl et al, 2024, European Journal of Cancer CrossRef
3. TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
   Xiaohang Liu et al, 2022, Frontiers in Immunology CrossRef
4. Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus
   Valérie Desmedt et al, 2023, European Journal of Cancer CrossRef
5. Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
   Yu Hua Chen et al, 2024, British Journal of Pharmacology CrossRef
6. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
   Mar Riveiro-Barciela et al, 2024, Gastroenterología y Hepatología CrossRef
7. A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma
   Goar Egoryan et al, 2024, Clinical Case Reports CrossRef
8. Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response
   Vishnupriyadevi Parvathareddy et al, 2023, Cancers CrossRef
9. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
   Jarushka Naidoo et al, 2023, Journal for ImmunoTherapy of Cancer CrossRef
10. Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
    Ting Yan et al, 2024, Frontiers in Immunology CrossRef
11. Immunbedingte Toxizitäten behandeln
    Severin Rodler et al, 2022, Uro-News CrossRef
12. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
    Faisal Fa'ak et al, 2023, Journal for ImmunoTherapy of Cancer CrossRef
13. Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis
    Dorte Lisbet Nielsen et al, 2022, Cancer Treatment Reviews CrossRef
14. Multiple drugs
    , 2021, Reactions Weekly CrossRef
15. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
    Mar Riveiro-Barciela et al, 2024, Revista Española de Enfermedades Digestivas CrossRef
16. Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review
    Sihan Tan et al, 2024, Cardiovascular Toxicology CrossRef
17. Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
    Amalia Anastasopoulou et al, 2023, Open Forum Infectious Diseases CrossRef
18. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
    Mar Riveiro-Barciela et al, 2024, Gastroenterología y Hepatología (English Edition) CrossRef